CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
XVR011 is a novel therapeutic candidate designed to neutralize SARS-CoV-2 using a unique nanobody-Fc fusion technology. Developed from llama-derived antibodies, it effectively blocks viral entry and replication, enhancing the immune response during critical phases of COVID-19 infection.
XVR011, ExeVir's clinical lead candidate has emerged from scientific research from labs of highly regarded virologist Xavier Saelens and biochemist Nico Callewaert.
Nonclinical data has recently been published in Cell and a preprint on BiorxIV. XVR011 is a nanobody-Fc fusion, has best-in-class potential, neutralizes SARS-CoV-2 and minimizes the development of lung damage in hamsters.
The lama-derived single-domain antibodies are smaller than human antibodies and can attach to parts of a virus th…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY
Belgium, ZWIJNAARDE - GENT
Type: Research institute
Activity type: Research Organisations
SME: No
GRANZER REGULATORY CONSULTING & SERVICES
Germany
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
France, Molsheim
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
